Disc Medicine FDA Rejection, Class Action
Analysis based on 14 articles · First reported Apr 07, 2026 · Last updated Apr 15, 2026
The market is impacted by the significant 22% drop in Disc Medicine's stock price, reflecting investor concern over the United States — Food and Drug Administration's rejection of its bitopertin drug application. This event also signals potential legal risks for Disc Medicine as Rosen Law Firm prepares a class action lawsuit, which could lead to further financial liabilities.
The United States — Food and Drug Administration issued a Complete Response Letter to Disc Medicine on February 13, 2026, stating that its new drug application for the bitopertin program could not be approved due to uncertainties requiring additional evidence. Following this news, Disc Medicine's stock price experienced a sharp decline of 22%. In response, Rosen Law Firm, a global investor rights law firm, has initiated an investigation into potential securities claims against Disc Medicine, alleging that the company may have issued materially misleading business information to the investing public. The firm is preparing a class action lawsuit to recover investor losses, encouraging affected shareholders to contact them.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard